BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.
A live webcast of the fireside chat can be accessed at https://wsw.com/webcast/guggen2/tngx/2036463 and will be available under the “Events & Presentations” tab on the “Investors” page on the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investor Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
IR@tangotx.com
Media Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.


Đề xuất
PHONO Marks 20th Anniversary and Secures New Orders at RE+ 2026
A Seattle Startup Brings Your Pet to Life on Your Phone and Laptop With the Avatar Mirroring Their Every Move in Real Time
HEARTBOT AI Wins Chunghwa Telecom Special Award at Meet Neo Star 2026
Allooloo Tops 100M Capital Markets AI Agent Traffic a Month
KONST Showcases “24/7 GPUs Delivered in Asia” at SC26, Offering AI Compute Services from Validation and Delivery to Round-the-Clock Operations
APEC CEO Summit 2026 Concludes Successfully in Shenzhen